[Efficacy of aphobazole in the treatment of anxiety disorders in patients with chronic cerebro-vascular insufficiency].
Sholomov
I I
II
Lutoshkina
E B
EB
Salina
E A
EA
D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D016896:Treatment Outcome
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D001562:Benzimidazoles; D009025:Morpholines